Replies to post #117598 on Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

You can call today's PR whatever you like, but it won't change the FACT that a stage 4 thymoma patient has stable disease and a ~6% tumor reduction in a Phase 1 safety trial.

Today's PR was a disgrace whether you look at from a GCP or a CSR perspective.

[biodoc]

Sunspotter,

I do believe you make some legitimate points. Just to be clear, I have built a considerable position in CTIX over the last two years. Please look at my past posts for my science perspective. A few thoughts:

First, the science is sound. Clinical trial results, on-going FDA trials, published pre-clinical data- all of this is readily available from the Cellceutix website, clinicaltrials.gov, and archived materials from the Polymedix days. I think you can easily verify ABSSSI Phase 2a and Phase 2b results. On these results alone, I believe you can see that Cellceutix has significant substance. The Cellceutix website has compelling pre-clinical data for Brilacidin rinse and Kevetrin. The background materials may help you wrap your arms around these compounds and gain a better understanding of the science. Also, consider that Dana Farber, MD Anderson, and the FDA are not easily swayed by weak science.

Second, Leo is not perfect. He has done an outstanding job of advancing the science but Leo has a huge and understandable emotional investment in Cellceutix and this shows in his press releases. However if you step back and take a close look at current clinical trials, the depth of the pipeline, and the relatively limited dilution over the last few years, it's very,very impressive that Leo's been able to advance the science so quickly on a limited budget. That's why it's easy for me to look past relatively minor missteps. At this point in development and not intending any disrespect to Leo, I do believe the company would be well served by a professional PR firm to help guide content and timing of future press releases. I also believe Leo has surrounded himself with very good people, especially Dr. Menon and Dr. Daniel Jorgensen. These guys are shakers and movers and I would not bet against them.

Having followed biotech for many years and with an appropriate background to understand the science, I honestly believe this is the strongest early/mid biotech pipeline I've ever seen. Brilacidin for ABSSSI alone is a company maker. The rest of the pipeline has mounting positive evidence of likely success but as with all biotech, it is not certain. Kevetrin Phase 1 will soon be completed. Trials for Brilacidin/oral mucositis and Prurisol (psoriasis) are enrolling and we could get an early read on results this year.

It is a challenging stretch for CTIX shareholders and many are understandably on edge. My confidence in the company is extremely high and I continue to add at these severely depressed prices. Let me know if you would like to discuss the science.

[muelch]

I don't completely disagree with you, but you're contradicting yourself.

The company clarified previously released data, which is good. If you're going to release data it should be qualified to a reasonable degree. It's better for them to say thymoma than cancer patient.

On one hand you're suggesting the company is giving false hope. I've seen them make no such claims that would remotely encourage patients to skip second or third line therapies and use Kevetrin instead. They aren't hyping the drug to media outlets, or if they are then it isn't working. But on the other hand you're suggesting it would be appropriate for them to disseminate the information to hospitals for compassionate use? I'm sorry but actually encouraging physicians to use the drug is much worse than providing information to investors so that they don't discount the drug's progression. I trust the FDA to understand statistics and hazard ratios, not MDs.

The information was only released after the sp started falling after a hit piece. The same thing occurred previously with info about a single metastatic spleen lesion, at least in terms of release after a significant drop to sp. The pattern so far has been to not release any data, except when the company's ability to raise capital is significantly jeopardized, which also directly jeopardizes what at this point can only be labeled a potentially very important drug.

These n of 1 snippets were not released to hype the drug or artificially inflate the sp, they were released to prevent the sp from being artificially deflated.

Kevetrin should not be used outside of clinical trials until it demonstrates more compelling/significant efficacy and safety data, period.

People also shouldn't post misleading articles designed to artificially deflate the sp so that they can make a profit from shorting the stock.

A SA author is exploiting one of these, the company is not.